Immedica’s partner Actinium presented four abstracts of Iomab-B at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
Stockholm, February 27, 2024 – Immedica’s partner Actinium Pharmaceuticals, Inc. presented four abstracts at the 2024 Tandem Meetings | Transplantation & Cellular Therapy (TCT) Meetings of ASTCT® (American Society for Transplantation and Cellular Therapy and CIBMTR® (Center for International Blood and Marrow Transplant Research) on February 21 – 24, 2024 in San Antonio, Texas. Two oral presentations and two poster presentations highlighted results from the positive Phase 3 SIERRA trial of Iomab-B ([131]I-Apamistamab). Altogether 10 oral presentations of the SIERRA results have been